𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke

✍ Scribed by Dr. Gregory J. del Zoppo; Klaus Poeck; Michael S. Pessin; Samuel M. Wolpert; Anthony J. Furlan; Andreas Ferbert; Mark J. Alberts; Justin A. Zivin; Lawrence Wechsler; Otto Busse; Ralph Greenlee Jr; Lawrence Brass; J. P. Mohr; Edward Feldmann; Werner Hacke; Carlos S. Kase; Jose Biller; Daryl Gress; Shirley M. Otis

Publisher
John Wiley and Sons
Year
1992
Tongue
English
Weight
928 KB
Volume
32
Category
Article
ISSN
0364-5134

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Efficacy and tolerance of recombinant ti
Efficacy and tolerance of recombinant tissue-type plasminogen activator in patients with thrombotic or embolic occlusions of leg-arteries
✍ Spengel, F.A. ;KοΏ½ffer, G. ;Stiegler, H. πŸ“‚ Article πŸ“… 1993 πŸ› Springer-Verlag 🌐 English βš– 641 KB

The efficacy and safety of recombinant tissue-type plasminogen activator (rt-PA) was evaluated in 46 patients with thrombembolic arterial occlusions in leg arteries, rt-PA was given over 1-4 h with a maximum dose of 18 mg. The effect of rt-PA treatment was determined as patency of the occluded arter

Tissue plasminogen activator and acute p
Tissue plasminogen activator and acute pulmonary embolism
✍ Samuel Z. Goldhaber; Craig M. Kessler; John Heit; John E. Markis; G. V. R. K. Sh πŸ“‚ Article πŸ“… 1988 πŸ› John Wiley and Sons 🌐 English βš– 714 KB

We assessed the efficacy and safety of peripheral intravenous recombinant human tissue-type plasminogen activator (rt-PA) in 47 patients with angiographically documented pulmonary embolism (PE). We administered 50 mg/2 h and, if necessary, an additional 40 mg/4 h. By 6 hours, 94% of the patients had